Latest Australian Biotech News

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

Regal Asian Investments Limited posted a sharp 92% decline in net profit for FY25 amid volatile Asian markets but maintained a fully franked 6 cent dividend and continued its on-market share buy-back program.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy to dose level 2 in its Phase 1/2 trial, showing promising early anti-tumor activity and a strong safety profile in gastrointestinal and neuroendocrine cancers.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.

Terragen Holdings has been granted a US patent for its microbial feed supplements, reinforcing its position in the animal probiotics market and supporting plans for US market entry.

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.